about
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchAnaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature.Osteoporosis and its implications for dental patients.Resection of granulomatous tissue resolves silicone induced hypercalcemia.Functional decline after incident wrist fractures--Study of Osteoporotic Fractures: prospective cohort study.Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.AIs: implications for fractures in perimenopausal women with breast cancer.Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.Amiodarone-associated optic neuropathy: a critical review.Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach.Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function.Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.One step, two steps, three steps more ... Directional vulnerability to falls in community-dwelling older people.Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.Endocrinology of menopause.Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.Incorporating Geriatric Medicine Providers into the Care of the Older Adult with Cancer.Own the Bone, a System-Based Intervention, Improves Osteoporosis Care After Fragility Fractures.Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.Osteoporosis Risk Calculators.Prior fractures are common in patients with subsequent hip fractures.Elevated incidence of fractures in women with invasive breast cancer.Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.Risk factors for falls in older patients with cancer.Online Educational Tool to Promote Bone Health in Cancer Survivors.Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.Neurocognitive deficits in older patients with cancer.Age influences the outcome of a slipping perturbation during initial but not repeated exposures.Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.Predicting Fracture Risk in Younger Postmenopausal Women: Comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative StudyImpact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugsEvaluation of Serious Adverse Drug ReactionsBarriers and solutions to osteoporosis care in patients with a hip fractureSolutions to the undertreatment of osteoporosis-related fracturesAn osteoporosis and fracture intervention program increases the diagnosis and treatment for osteoporosis for patients with minimal trauma fracturesAcute vertebral fracture
P50
Q26782621-DA3B1C15-D7CD-401E-AB93-7F8418B17199Q30668580-C2657F53-F67A-41ED-B088-05E832F0B2C6Q33331310-31F5E6A6-C4F1-4A3A-8EB3-CF34580CC0F8Q33716914-214B5C41-60C1-4F72-9B2C-47ED4DC34C59Q33977118-82192ACD-B485-470D-A7AA-4D19A1EE3491Q34223200-88941814-F297-4C76-A853-FE22B5E139B9Q34370603-E33E87AC-4758-4FEB-B619-22D64D313A93Q34526604-A0B70B1D-793D-431B-9124-09F4BB1125DEQ34680563-30E7F9DD-660A-4869-BD1A-E89B43A01724Q35878060-64656E04-B6BE-4C72-987F-E72895F73302Q36237854-BCFE4A9B-7368-4DC7-86E6-70FC573A5532Q36692517-EC3B6F38-DF9E-4CD3-8F92-E7F09FA00E8DQ36831731-7F62F711-9BA2-415A-A2C8-89C994286B8FQ36920523-3D80D1D0-2BD3-43F7-A98A-84A8E27834D2Q37270904-2FDD204D-A403-4428-AB23-6FA0629ECE2CQ37336471-5B417FF5-7264-4CDC-A335-4C79781B5A26Q37347519-7CEABCD2-417C-4D45-BC2E-4BA78FC6BB5CQ37624891-879D5162-6967-41A0-AFBE-54C01837C5FFQ38067477-403F314D-39F0-44E3-828A-AA8172284C7EQ38833288-A9728196-2C00-40BD-9531-F8DC2D9A5B2EQ38950570-29D7F915-B61F-4477-B407-BE5619804526Q39077620-AC72272C-17E9-442E-A3F3-69645EF87AA6Q39109069-C27965D7-0958-49FA-A52E-1F1528584846Q39454959-8009797A-0786-4029-B6A5-E6A1BA20EE9AQ40225590-15552813-8051-4AED-B0BC-51123A1695BBQ41464715-406AD6CB-038D-4A23-A063-3B9A37FFA124Q47191854-A0028F7A-2C86-458E-9AE0-374CDB3F91A9Q47716693-FB75C580-EC55-4409-BABC-E80929AD3243Q48330464-9A1C112B-77DB-4982-8F7E-DE74B540D490Q49344279-384160C9-9A5C-4115-BBBF-617036A2A9D1Q50531076-6A2FD9C6-F955-4C84-B909-9C6407BE43B8Q52116661-4C751380-676D-4E98-8717-23E871B9E374Q53777467-FEC89864-1AD2-41A4-BEC4-00A8B058A3CBQ58545509-B1C679BD-B7C7-412F-863E-F196BEC8E10BQ60148394-CCD993E2-0663-4B74-BF10-196D334AE3D1Q60148400-DB588890-5093-4029-9D82-1732DC325495Q73899013-A62000E0-4C93-45A8-9023-6198A50FB648Q79811387-8D521E88-4327-4DA0-A283-A39E646E7789Q81858573-43502AFC-055A-46BD-BA78-A862B3C796DFQ84025516-316B9B91-0675-4A9C-8E43-61D283D8ADB6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Beatrice J Edwards
@ast
Beatrice J Edwards
@en
Beatrice J Edwards
@es
Beatrice J Edwards
@nl
type
label
Beatrice J Edwards
@ast
Beatrice J Edwards
@en
Beatrice J Edwards
@es
Beatrice J Edwards
@nl
prefLabel
Beatrice J Edwards
@ast
Beatrice J Edwards
@en
Beatrice J Edwards
@es
Beatrice J Edwards
@nl
P106
P1153
7202177236
P21
P31
P496
0000-0002-7900-5159